|
Tags: Manual revert Replaced |
| (5 intermediate revisions by the same user not shown) |
| Line 7: |
Line 7: |
|
| |
|
| ==Sandbox begins below== | | ==Sandbox begins below== |
|
| |
| ====3.1.7 Multiplex testing====
| |
| As the pandemic has progressed and test manufacturers have become more experienced with SARS-CoV-2 test development, multiplex testing has become an option. The multiplex assay—an immunoassay test able to measure multiple analytes in a single test—is certainly not new in itself. In 1989, R. Ekins developed the ambient analyte theory, which stated that miniaturizing an immunoassay can lead to an improved limit of detection (LOD). That work influenced the future development of microarray multiplex technology principles.<ref name="TigheELISA15">{{Cite journal |last=Tighe |first=Patrick J. |last2=Ryder |first2=Richard R. |last3=Todd |first3=Ian |last4=Fairclough |first4=Lucy C. |date=2015-04 |title=ELISA in the multiplex era: Potentials and pitfalls |url=https://onlinelibrary.wiley.com/doi/10.1002/prca.201400130 |journal=PROTEOMICS – Clinical Applications |language=en |volume=9 |issue=3-4 |pages=406–422 |doi=10.1002/prca.201400130 |issn=1862-8346 |pmc=PMC6680274 |pmid=25644123}}</ref> By 2013, development of multiplex protein immunoassays was becoming increasingly prominent.<ref name="TigheELISA15" />
| |
|
| |
| As of September 2021, eighteen "multi-analyte" ''in vitro'' molecular diagnostic tests are shown as receiving EUAs by the FDA, four of them even authorized for CLIA waived testing.<ref name="FDAInVitroEUAs21">{{cite web |url=https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2 |title=In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2 |publisher=U.S. Food and Drug Administration |date=07 September 2021 |accessdate=07 September 2021}}</ref> Common additional targets for analysis among the various kits include influenza A, influenza B, and respiratory syncytial virus (RSV).<ref name="FDAInVitroEUAs21" /> However, several multiplex test kits cover an even broader array of respiratory-affecting organism types and subtypes such as adenovirus and a few other coronavirus types, to name a few. Kits include the ePlex Respiratory Pathogen Panel 2<ref name="HintonePlex20">{{cite web |url=https://www.fda.gov/media/142902/download |format=PDF |title=ePlex Respiratory Pathogen Panel 2 (ePlex RP2 Panel) |author=Hinton, D.M. |publisher=U.S. Food and Drug Administration |date=07 October 2020 |accessdate=19 September 2021}}</ref>, the NxTAG Respiratory Pathogen Panel + SARS-CoV-2<ref name="HintonNxTAG21">{{cite web |url=https://www.fda.gov/media/146492/download |format=PDF |title=NxTAG Respiratory Pathogen Panel + SARS-CoV-2 |author=Hinton, D.M. |publisher=U.S. Food and Drug Administration |date=03 March 2021 |accessdate=19 September 2021}}</ref>, the QIAstat-Dx Respiratory SARS-CoV-2 Panel<ref name="HintonQIAstat21">{{cite web |url=https://www.fda.gov/media/136569/download |format=PDF |title=QIAstat-Dx Respiratory SARS-CoV-2 Panel |author=Hinton, D.M. |publisher=U.S. Food and Drug Administration |date=29 July 2021 |accessdate=19 September 2021}}</ref>, and the BioFire Respiratory Panel 2.1-EZ.<ref name="HintonBioFireRes21">{{cite web |url=https://www.fda.gov/media/142693/download |format=PDF |title=BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) |author=Hinton, D.M. |publisher=U.S. Food and Drug Administration |date=30 August 2021 |accessdate=19 September 2021}}</ref> (Of the four, the BioFire panel is approved for CLIA waived testing.<ref name="FDAInVitroEUAs21" />)
| |
|
| |
| Multiplexing provides a variety of benefits for laboratories and patients. In their 2015 paper on ELISA and multiplex technologies, Tighe ''et al'' find that multiplexed immunoassays have the potential to decrease diagnosis times and reduce assay costs. "At the same time, such multiplexing offers more comprehensive analysis whether for research purposes, differential diagnoses, or monitoring of therapeutic interventions."<ref name="TigheELISA15" /> They also note the potential for improved health surveillance of patients, catching early-onset diseases by looking for informative biomarkers.<ref name="TigheELISA15" /> From the perspective of diagnosing infections of SARS-CoV-2 or influenza, the CDC adds that multiplexing helps preserve testing supplies that may be in short supply, conduct more tests in a given time period, and paint a clearer picture of both viruses and their prevalence in a given population.<ref name="CDCInflu21">{{cite web |url=https://www.cdc.gov/coronavirus/2019-ncov/lab/multiplex.html |title=CDC’s Influenza SARS-CoV-2 Multiplex Assay and Required Supplies |author=Centers for Disease Control and Prevention |publisher=Centers for Disease Control and Prevention |date=13 July 2021 |accessdate=19 September 2021}}</ref>
| |
